Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Smoke Without Fire: Unichem Divests Domestic Business To Torrent

Executive Summary

Two years after denying sell-off plans, Unichem Laboratories is divesting its branded business in India and Nepal to peer Torrent for around $558m. The deal catapults Torrent to the top league on the domestic market and also sets the tone for potential consolidation in the Indian pharma space at more realistic valuations.

You may also be interested in...



Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine

Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel